Download Files:
SARS-CoV-2-IN-13
$150 – $1,200
Products Details
Product Description
– SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].
Web ID
– HY-144770
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C13H8Cl2N2O4
References
– [1]Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295.
CAS Number
– 56961-10-5
Molecular Weight
– 327.12
Compound Purity
– 98.90
SMILES
– O=C(C1=C(C=CC(Cl)=C1)O)NC2=CC(Cl)=C(C=C2)[N+]([O-])=O
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : ≥ 125 mg/mL
Target
– SARS-CoV
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
